Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 31Advanced Solid Tumors 25Advanced Solid Tumor 24Carcinoma, Non-Small-Cell Lung 20Neoplasms 15Solid Tumor 12Prostatic Neoplasms 12Multiple Myeloma 12Neoplasm Metastasis 11Recurrence 10Pancreatic Neoplasms 10Small Cell Lung Carcinoma 9Ovarian Neoplasms 9Lung Neoplasms 9Stomach Neoplasms 8Melanoma 8Lymphoma, Large B-Cell, Diffuse 8Leukemia, Myeloid, Acute 8Carcinoma, Hepatocellular 8Triple Negative Breast Neoplasms 7Sarcoma 7Colorectal Neoplasms 7Uterine Cervical Neoplasms 6Solid Tumors 6Carcinoma, Transitional Cell 5Advanced Solid Tumour 5Squamous Cell Carcinoma of Head and Neck 4Nasopharyngeal Carcinoma 4Myelodysplastic Syndromes 4Lymphoma 4

Interventions

andecaliximab 1S 1 (combination) 1Oxaliplatin 1Nivolumab 1Injections 1Immunotherapy, Adoptive 1Docetaxel 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Gastric Adenocarcinoma × Injections × Clear all
NCT05705635 2023-01-31

A Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2 Unknown
100 enrolled
Gastrointestinal

Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡